Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Accumulated Expenses (2019 - 2025)

Keros Therapeutics filings provide 7 years of Accumulated Expenses readings, the most recent being $16.0 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 23.15% to $16.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $16.0 million, a 23.15% decrease, with the full-year FY2025 number at $16.0 million, down 23.15% from a year prior.
  • Accumulated Expenses hit $16.0 million in Q4 2025 for Keros Therapeutics, up from $15.2 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $22.2 million in Q3 2024 to a low of $5.5 million in Q1 2021.
  • Median Accumulated Expenses over the past 5 years was $12.5 million (2023), compared with a mean of $12.6 million.
  • Biggest five-year swings in Accumulated Expenses: surged 87.71% in 2021 and later plummeted 31.55% in 2025.
  • Keros Therapeutics' Accumulated Expenses stood at $7.3 million in 2021, then soared by 73.77% to $12.8 million in 2022, then surged by 40.5% to $17.9 million in 2023, then rose by 16.48% to $20.9 million in 2024, then decreased by 23.15% to $16.0 million in 2025.
  • The last three reported values for Accumulated Expenses were $16.0 million (Q4 2025), $15.2 million (Q3 2025), and $20.0 million (Q2 2025) per Business Quant data.